-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Due to high heterogeneity, poor prognosis, and high risk of recurrence and metastasis, triple-negative breast cancer has become a stubborn "fortress"
that needs to be overcome urgently in breast cancer research.
Some triple-negative breast cancers, such as the luminal androgen receptor (LAR) subtype, are less sensitive
to existing precision therapy strategies.
that needs to be overcome urgently in breast cancer research.
Some triple-negative breast cancers, such as the luminal androgen receptor (LAR) subtype, are less sensitive
to existing precision therapy strategies.
The reporter learned on the 18th that the latest research by Chinese medical experts found that the combination of targeted "iron death" and immunotherapy
.
This may be a new direction
for precision treatment of LAR-type triple-negative breast cancer.
It is reported that "iron death" is a newly discovered form of cell death by scientists in recent years, which has been widely concerned
in tumor biology research and clinical treatment.
.
This may be a new direction
for precision treatment of LAR-type triple-negative breast cancer.
It is reported that "iron death" is a newly discovered form of cell death by scientists in recent years, which has been widely concerned
in tumor biology research and clinical treatment.
A study led by Professor Shao Zhimin and Professor Jiang Yizhou of the Department of Breast Surgery of Fudan University Cancer Hospital showed that "iron death" is more active in LAR-type triple-negative breast cancer, and glutathione metabolism with "glutathione peroxidase 4" (GPX4) as the core plays an important role
in the regulation of "iron death" in LAR-type triple-negative breast cancer.
in the regulation of "iron death" in LAR-type triple-negative breast cancer.
The team further explored and found that GPX4 inhibitors can not only inhibit tumors by promoting "iron death", but also reshape the tumor immune microenvironment
.
GPX4 inhibitors in combination with immunotherapy can further activate T cells in the tumor microenvironment (T cells are called T lymphocytes, which are an important part of immunity in the body), and the efficacy of dual-drug therapy is significantly higher than that of monotherapy
.
This means that GPX4 inhibitors combined with immunotherapy may become a potential new treatment strategy
for LAR-type triple-negative breast cancer.
The relevant research results were published online in the internationally renowned journal Cell Metabolism late on the night of the 17th Beijing time
.
.
GPX4 inhibitors in combination with immunotherapy can further activate T cells in the tumor microenvironment (T cells are called T lymphocytes, which are an important part of immunity in the body), and the efficacy of dual-drug therapy is significantly higher than that of monotherapy
.
This means that GPX4 inhibitors combined with immunotherapy may become a potential new treatment strategy
for LAR-type triple-negative breast cancer.
The relevant research results were published online in the internationally renowned journal Cell Metabolism late on the night of the 17th Beijing time
.
It is understood that there are many forms of cell "death", "iron death" is one of them, because this form of death is driven by "iron-dependent lipid peroxidation", regulated by multiple metabolic pathways
.
"'Iron death' is a regulatory cell death method closely related to metabolism discovered in recent years, which is active in the field of oncology research, and we try to start research from this perspective to discover a new breakthrough in the treatment of triple-negative breast cancer
.
" Professor Shao Zhimin said
.
.
"'Iron death' is a regulatory cell death method closely related to metabolism discovered in recent years, which is active in the field of oncology research, and we try to start research from this perspective to discover a new breakthrough in the treatment of triple-negative breast cancer
.
" Professor Shao Zhimin said
.
The study found that the cellular metabolic pathways and metabolites associated with "iron death" were highly active in LAR-type triple-negative breast cancer, suggesting that it may be the most sensitive subtype to "iron death".
On the other hand, glutathione metabolism with GPX4 as the core is significantly upregulated in the LAR subtype, which is the most important way
for tumors of this subtype to escape "iron death".
(End)
On the other hand, glutathione metabolism with GPX4 as the core is significantly upregulated in the LAR subtype, which is the most important way
for tumors of this subtype to escape "iron death".
(End)
